Synonyms: AS-602801 | AS602801 | PGL-5001 | PGL5001
Compound class:
Synthetic organic
Comment: Bentamapimod (a.k.a. PGL-5001 and AS602801) is novel and orally active Jun kinase inhibitor (JNK1= MAPK8 and JNK2= MAPK9). It has shown preclinical efficacy that may be applied to the treatment of endometriotic lesions [1,3]. It also inhibits cancer stem cells in vitro and in vivo [2]. It was originally developed by Merck Seroneo (JNK-I AS602801) and then in-licensed by PregLem and re-named PGL5001 (PGL5 may also be used).
|
|
Bioactivity Comments |
Bentamapimod is likely one of the compounds claimed in Merck Serono's patent US20130267512A1, as the SMILES string returns this patent via a SureChEMBL open patent search. No potency data is provided in the patent for the direct inhibition of the JNK kinases, so we are unable to validate the compound's primary molecular target, pending publication in peer reviewed literature. |